<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1242">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512118</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI153</org_study_id>
    <nct_id>NCT04512118</nct_id>
  </id_info>
  <brief_title>CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients</brief_title>
  <official_title>CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CT signs that are evocative of lung COVID-19 infections have been extensively described,
      whereas 18F-FDG-PET signs have not. Our current study aimed to identify specific COVID-19
      18F-FDG-PET signs in patients that were (i) suspected to have a lung infection based on
      18F-FDG-PET/CT recorded during the COVID-19 outbreak and (ii) whose COVID-19 diagnosis was
      definitely established or excluded by appropriate viral testing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Actual">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analysis of pulmonary lobes</measure>
    <time_frame>1 day</time_frame>
    <description>Visual analysis of the pulmonary lobes by calculating a extent score for each patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of metabolic activity</measure>
    <time_frame>1 day</time_frame>
    <description>Measurement of metabolic activity with SUV max of lung areas with CT abnormalities</description>
  </secondary_outcome>
  <enrollment type="Actual">22</enrollment>
  <condition>Presence of COVID-19 Compatible CT Abnormalities</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET-CT of 18F-FDG</intervention_name>
    <description>Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with suspicion of lung involvement in COVID19 context
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient coming to nuclear medicine for 18F-flurodesoxyglucose (FDG) positron emission
             tomography computed tomography (PET-CT) with suspicion of lung involvement

          -  patient affiliated to a social security scheme or equivalent

          -  adult patient having been informed of the study

        Exclusion Criteria:

          -  patient with a negative covid 19 test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHRU of Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Grand Est</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Antoine VERGER</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>18F FDG PET</keyword>
  <keyword>lung infection</keyword>
  <keyword>CT</keyword>
  <keyword>seriological tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

